ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 80 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,000,100 | +296.9% | 146,000 | +500.8% | 0.00% | +200.0% |
| Q2 2023 | $251,991 | -23.1% | 24,300 | -40.0% | 0.00% | 0.0% |
| Q1 2023 | $327,645 | +69.8% | 40,500 | +204.5% | 0.00% | – |
| Q4 2021 | $193,000 | -34.6% | 13,300 | -18.9% | 0.00% | -100.0% |
| Q3 2021 | $295,000 | -77.0% | 16,400 | -77.6% | 0.00% | -66.7% |
| Q2 2021 | $1,285,000 | -15.5% | 73,200 | +21.4% | 0.00% | -25.0% |
| Q1 2021 | $1,520,000 | +398.4% | 60,300 | +27.8% | 0.00% | +300.0% |
| Q4 2020 | $305,000 | +408.3% | 47,200 | +103.4% | 0.00% | – |
| Q3 2020 | $60,000 | +42.9% | 23,200 | -10.4% | 0.00% | – |
| Q2 2020 | $42,000 | +16.7% | 25,900 | -25.4% | 0.00% | – |
| Q1 2020 | $36,000 | -67.0% | 34,700 | -40.1% | 0.00% | – |
| Q4 2019 | $109,000 | -34.7% | 57,900 | -62.6% | 0.00% | – |
| Q3 2019 | $167,000 | – | 155,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |